Regeneron Pharmaceuticals, Inc. (REGN) Misses Q1 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $803.31 -0.52%
EPS Growth %: +35.8%
Financial Fact:
Total other income (expense): 3.08M
Today's EPS Names:
OMID, BCML, CZNC, More
EPS Growth %: +35.8%
Financial Fact:
Total other income (expense): 3.08M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plumas Bancorp (PLBC) Tops Q3 EPS by 15c
- GE Vernova rises on BofA order growth forecast
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
